Targeted therapy for lung cancer

Anti-Cancer Drugs

Volumn 23, Issue 10, 2012, Pages 1016-1021

  Petrosyan, Frunze ^a   Daw, Hamed ^a   Haddad, Abdo ^a   Spiro, Timothy ^a  

^a FAIRVIEW HOSPITAL   (United States)

Author keywords

crizotinib; erlotinib; gefitinib; non small cell lung cancer; targeted therapy

Indexed keywords

AFATINIB; ANAPLASTIC LYMPHOMA KINASE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CRIZOTINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; NERATINIB; PEMETREXED; PF 0299804; PLACEBO; PZ 02341066; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; CANCER CHEMOTHERAPY; CANCER SURVIVAL; DRUG EFFICACY; DRUG SAFETY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; LUNG NON SMALL CELL CANCER; MUTATION; NONSQUAMOUS NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; QUINAZOLINES;

EID: 84867580380     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3283585149     Document Type: Review

References (48)

1. Cancer facts and figures 2012, cited 12 February 2012. Available at: http://www.cancer.org [Accessed 12 February 2012].
2. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355:2542-2550.
3. Yang P, Allen MS, Aubry MC, Wampfler JA, Marks RS, Edell ES, et al. Clinical features of 5,628 primary lung cancer patients: Experience at Mayo Clinic from 1997 to 2003. Chest 2005; 128:452-462.
4. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol 2011; 12:175-180.
5. Toh CK, Gao F, Lim WT, Leong SS, Fong KW, Yap SP, et al. Never-smokers with lung cancer: Epidemiologic evidence of a distinct disease entity. J Clin Oncol 2006; 24:2245-2251.
6. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129-2139.
7. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004; 304:1497-1500.
8. PaoW, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al. Egf receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004; 101:13306-13311.
9. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small cell lung cancer. Nature 2007;448-561.
10. Felsher DW. Cancer revoked: Oncogenes as therapeutic targets. Nat Rev Cancer 2003; 3:375-380.
11. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353:123-132.
12. Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (iressa survival evaluation in lung cancer). Lancet 2005; 366:1527-1537.
13. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the ideal 1 trial) [corrected]. J Clin Oncol 2003; 21:2237-2246.
14. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009; 361:958-967.
15. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362:2380-2388.
16. Riely GJ, Politi KA, Miller VA, Pao W. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res 2006; 12:7232-7241.
17. Jackman DM, Yeap BY, Sequist LV, Lindeman N, Holmes AJ, Joshi VA, et al. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res 2006; 12:3908-3914.
18. Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 2003; 290:2149-2158.
19. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinumbased chemotherapy. J Clin Oncol 2000; 18:2095-2103.
20. Ciuleanu T, Stelmakh L, Cicenas S, Miliauskas S, Grigorescu AC, Hillenbach C, et al. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (titan): A randomised multicentre, open-label, phase 3 study. Lancet Oncol 2012; 13:300-308.
21. Vamvakas L, Agelaki S, Kentepozidis NK, Karampeazis A, Pallis AG, Christophyllakis C, et al. Pemetrexed (MTA) compared with erlotinib (ERL) in pretreated patients with advanced non-small cell lung cancer (NSCLC): Results of a randomized phase III hellenic oncology research group trial [abstract]. J Clin Oncol 2010; 28:7519.
22. Zhou C, Wu YL, Chen G, Feng J, Liu XQ,Wang C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (optimal, ctong-0802): A multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011; 12:735-742.
23. Rosell E, Gervais R, Vergnenegre A, Massuti B, Felip E, Cardenal F, et al. The EURTAC study: Interim results of a phase III randomized trial of erlotinib vs. chemotherapy in advanced nonsmall-cell lung cancer patients with epidermal growth factor receptor activating mutation [abstract]. J Clin Oncol 2011; 29:7503.
24. Mok TS,Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361:947-957.
25. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (wjtog3405): An open label, randomised phase 3 trial. Lancet Oncol 2010; 11:121-128.
26. Zhou C,Wu YL, Chen G, Feng J, Liu X,Wang C, et al. Efficacy results from the randomized phase III optimal (CTONG 0802) study comparing first-line erlotinib versus carboplatin (CBDCA) plus gemcitabine (GEM), in Chinese advanced nonsmall-cell lung cancer (NSCLC) patients (PTS) with EGFR activating mutations [abstract]. Ann Oncol 2010; 21:LBA13.
27. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005; 353:786-792.
28. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005; 2:e73.
29. Balak MN, Gong Y, Riely GJ, Somwar R, Li AR, Zakowski MF, et al. Novel d761y and common secondary t790m mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 2006; 12:6494-6501.
30. Bean J, Brennan C, Shih JY, Riely G, Viale A,Wang L, et al. Met amplification occurs with or without t790m mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 2007;20932-20937.
31. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. Met amplification leads to gefitinib resistance in lung cancer by activating erbb3 signaling. Science 2007; 316:1039-1043.
32. Riely GJ. Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. J Thorac Oncol 2008; 3:S146-S149.
33. Kwak EL, Sordella R, Bell DW, Godin-Heymann N, Okimoto RA, Brannigan B, et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci USA 2005; 102: 7665-7670.
34. Miller VA, Hirsh V, Cadranal J, Chen YM, Park K, Kim SW, et al. Phase IIb/III double-blind randomized trial of BIBW 2992, an irreversible inhibitor of EGFR/HER1 and HER2+ best supportive care (bsc) versus placebo +bsc in patients with nsclc failing 1-2 lines of chemotherapy and erlotinib or gefitinib (lux-lung 1). Oral presentation at The European Society of Medical Oncology (ESMO) annual meeting, Milan, October 2010: [Abstract LBA1].
35. Regales L, Gong Y, Shen R, Stanchina E, Vivanco I, Goel A, et al. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J Clin Invest 2009; 119: 3000-3010.
36. Janjigian YY, Groen HJ, Horn L, Smit EF, Fu Y, Wang F, et al. Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib [abstract]. J Clin Oncol 2011; 29:7525.
37. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010; 363:1693-1703.
38. Riely GJ, Chaft JE, Ladanyi M, Kris MG. Incorporation of crizotinib into the NCCN guidelines. J Natl Compr Canc Netw 2011; 9:1328-1330.
39. NCCN guidelines version 2; 2012 non-small-cell lung cancer. Available at: http://www.nccn.org [Accessed 1 September 2012].
40. Shaw AT, Solomon B, Kenudson MM. Crizotinib and testing for ALK. J Natl Compr Canc Netw 2011; 9:1335-1341.
41. Rodig SJ, Mino-Kenudson M, Dacic S, Yeap BY, Shaw A, Barletta JA, et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 2009; 15:5216-5223.
42. Takeuchi K, Choi YL, Togashi Y, Soda M, Hatano S, Inamura K, et al. KIF5BALK, a novel fusion oncokinase identified by an immunohistochemistrybased diagnostic system for ALK-positive lung cancer. Clin Cancer Res 2009; 15:3143-3149.
43. Mino-Kenudson M, Chirieac LR, Law K, Hornick JL, Lindeman N, Mark EJ, et al. A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res 2010; 16:1561-1571.
44. Paik JH, Choe G, Kim H, Choe JY, Lee HJ, Lee CT, et al. Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: Correlation with fluorescence in situ hybridization. J Thorac Oncol 2011; 6:466-472.
45. Yi ES, Boland JM, Maleszewski JJ, Roden AC, Oliveira AM, Aubry MC, et al. Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH. J Thorac Oncol 2011; 6:459-465.
46. Takeuchi K, Choi YL, Soda M, Inamura K, Togashi Y, Hatano S, et al. Multiplex reverse transcription-pcr screening for EML4-ALK fusion transcripts. Clin Cancer Res 2008; 14:6618-6624.
47. Choi YL, Takeuchi K, Soda M, Inamura K, Togashi Y, Hatano S, et al. Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. Cancer Res 2008; 68:4971-4976.
48. Li T, Mack PC, Desai S, Kelly K, Cooc J, Danenberg PV, et al. Large-scale screening of ALK fusion oncogene transcripts in archival NSCLC tumor specimens using multiplexed RT-PCR assays [abstract]. J Clin Oncol 2011; 29 (Suppl):10520.